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Abstract
Objective
We report a second family with autosomal dominant transportinopathy presenting with congenital or early-onset myopathy and slow progression, causing proximal and less pronounced
distal muscle weakness.
Methods
Patients had clinical examinations, muscle MRI, EMG, and muscle biopsy studies. The
MYOcap gene panel was used to identify the gene defect in the family. Muscle biopsies were
used for histopathologic and protein expression studies, and TNPO3 constructs were used to
study the eﬀect of the mutations in transfected cells.
Results
We identiﬁed a novel heterozygous mutation, c.2757delC, in the last part of the transportin-3
(TNPO3) gene in the aﬀected family members. The mutation causes an almost identical
frameshift aﬀecting the stop codon and elongating the C-term protein product of the TNPO3
transcript, as was previously reported in the ﬁrst large Spanish-Italian LGMD1F kindred.
TNPO3 protein was increased in the patient muscle and accumulated in the subsarcolemmal
and perinuclear areas. At least one of the cargo proteins, the splicing factor SRRM2 was
normally located in the nucleus. Transiently transfected mutant TNPO3 constructs failed to
localize to cytoplasmic annulate lamellae pore complexes in cells.
Conclusions
We report the clinical, molecular genetic, and histopathologic features of the second transportinopathy family. The variability of the clinical phenotype together with histopathologic
ﬁndings suggests that several molecular pathways may be involved in the disease pathomechanism, such as nucleocytoplasmic shuttling, protein aggregation, and defective protein
turnover.
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Glossary
AL = annulate lamella; ALPC = annulate lamellae pore complex; BSA = Bovine serum albumin; CK = creatine kinase; DAB =
diaminobenzinide; HA = hemagglutinin; IF = immunoﬂuorescent; IHC = immunohistochemistry; PBS = Phosphate buﬀered
saline; PC = pore complex; RBM4 = RNA binding motif protein 4; RT = room temperature; SG = stress granule; SR = serine/
arginine rich; SRRM2 = SR repetitive matrix 2; SQSTM1 = sequestosome 1; TA = tibialis anterior; TDP-43 = TAR DNAbinding protein 43; TIA1 = T-cell-restricted intracellular antigen-1; TNPO = transportin-3; WT = wild type.

The limb-girdle muscular dystrophies form a heterogeneous
group of genetically transmitted myopathies with predominantly proximal, progressive muscle weakness.1 To date, 8
forms of dominant limb-girdle muscular dystrophy with known
genetic cause have been identiﬁed; however, a new nomenclature has recently been proposed,2 in which only 4 dominant
forms fulﬁlled the required criteria: LGMD D1 DNAJB6 related, D2 TNPO3 related, D3 heterogeneous nuclear ribonucleoprotein D like related, and D4 calpain3 related.
A dominant mutation in the TNPO3 gene was found to cause
LGMD1F in a large Spanish-Italian family with proximal limb
and axial muscle weakness.3,4 The causative mutation,
c.2771delA p.*924Cext*15 in exon 22, results in the extension of
the reading frame by 15 additional amino acids. There was wide
variability in the age at onset and disease severity,3 and also,
nonpenetrance was observed.5 Muscle weakness and atrophy of
the lower limbs were prominent. Additional features were dysphagia, arachnodactyly, joint contractures, scapular winging, and
hyperlordosis in some of the patients.3,6 Muscle histopathology
was characterized by myopathic changes, including nuclear pathology, myoﬁbrillar protein accumulation in the cytoplasm, and
rimmed vacuolar pathology corresponding to accumulated
autophagosomal membranes at the ultrastuctural level.6,7
Transportin-3 (TNPO3) belongs to the importin beta superfamily. It facilitates the nuclear import of Ser/Arg-rich
(SR) proteins.8 SR motifs are commonly found on RNAbinding proteins associated with splicing. TNPO3 has also
been identiﬁed as essential for HIV infection, and loss of
TNPO3 function is protective against HIV.9 The role of
TNPO3 in skeletal muscle and how mutations aﬀect its
function and lead to muscle disease have not been described.

Patients
A Swedish family with 3 patients representing subsequent generations, the proband (II-1), his mother (I-3), and his son (III-1),
was included in this study (ﬁgure 1). The patients were followed
up since early childhood because of walking diﬃculties or hypotonia at birth. All underwent neurologic examinations, muscle
biopsy, and muscle MRI studies. EMG ﬁndings and creatine
kinase (CK) levels were available in the proband and his mother.
Muscle biopsies were performed at diﬀerent time points: for I-3,
at ages 31 and 48 years (both from the tibialis anterior muscle,
TA); for II-1, at ages 3, 24, and 35 years (all from the TA); and
for III-1, at age 16 months (vastus lateralis).
2
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Figure 1 Pedigree

The affected family members were included in this study. The proband (II-1)
is indicated with an arrow.

Standard protocol approvals, registrations,
and patient consents
All participants provided appropriate consent, and the study
was approved by the IRB of Tampere University Hospital.

Methods
Molecular genetics
Targeted massively parallel sequencing was performed for
DNA samples of patients II-1 and III-1, as previously described,10 and sample I-3 was Sanger sequenced. The sequencing library was enriched using the probes of MYOcap
v3 gene panel that is targeted to the exons of 265 genes
known or predicted to cause muscular dystrophy or
myopathy.
Histologic techniques
Snap-frozen muscle biopsies were processed into sections for
histologic and immunohistochemical stainings. Conventional
hematoxylin and eosin (H&E), Herovici, modiﬁed Gomori
trichrome, and nicotinamide adenine dinucleotide tetrazolium reductase staining techniques were applied.11
For immunohistochemistry (IHC), the Ventana GX automated immunostainer was used to get 3,39-diaminobenzidine
immunolabeling, followed by hematoxylin and bluing counterstain (all by Roche Tissue Diagnostics/Ventana Medical
Systems, Tucson, AZ).
Neurology.org/NG

Immunoﬂuorescent (IF) stainings were performed manually.
The frozen muscle sections were ﬁxed in 4% paraformaldehyde
for 15 minutes, permeabilized with 0.05% Triton X-100 in
phosphate buﬀered saline (PBS) for 10 minutes, and blocked
with 2% bovine serum albumin (BSA) in PBS for 30 minutes.
Primary antibody incubation was performed overnight at 8°C.
After PBS washes, Alexa-488 and Alexa-546 Fluor–conjugated
secondary antibodies were used for detection at room temperature (RT) for 1 hour. Hoechst nuclear conterstain was
performed before mounting in Fluoromount (Sigma-Aldrich)
medium. The following primary antibodies were used: polyclonal anti-TNPO3 antibody (C-term) (Abcam ab109386),
polyclonal anti-p62 (Millipore/Sigma P0067), monoclonal
anti-TAR DNA-binding protein 43 (TDP-43) (Sigma-Aldrich
WH0023435M1-1), polyclonal anti-ubiquitin (Dako Z0458),
polyclonal anti-myotilin (ProteinTech 10731-1-AP), monoclonal anti-desmin (Abcam ab32362), monoclonal anti-alpha-Bcrystallin (CRYAB) (Leica Biosystems NCL-ABCrys-512),
monoclonal anti-tropomyosin (Abcam ab7786), polyclonal
anti-CHCHD10 (Novus Biologicals NBP1-91169), polyclonal
anti-RNA binding motif protein 4 (RBM4) (Atlas Antibodies
HPA047849), and polyclonal anti-serine/arginine repetitive
matrix 2 (SRRM2) (Abcam ab122719).
Western blotting
Frozen muscle biopsies were homogenized in Laemmli sample buﬀer and heated at 98°C for 5 minutes to prepare tissue
lysates.
Conventional
sodium
dodecyl
sulphate
polyacrylamide gel electrophoresis and Western blotting
protocols were used, with 4%–20% precast TGX (Bio-Rad
Laboratories, Hercules, CA) and Trans-Blot Turbo System
(Bio-Rad) for protein transfer onto polyvinylidene diﬂuoride
membranes. For immunodetection, the membrane was incubated overnight at 8°C with anti-TNPO3 antibody (Abcam
ab109386) at 1/500 dilution in tris-buﬀered saline with
tween-20/5% skimmed milk powder. The next day, after
horseradish peroxidase-conjugated secondary antibody incubation for 1 hour at RT, the bands were detected using
enhanced chemiluminescence (SuperSignal West Femto
Maximum Sensitivity Substrate, Thermo Fisher Scientiﬁc).
After blotting, the gels were recovered and stained with
Coomassie blue for myosin heavy chain, which was used as
a loading control. ChemiDoc reader and ImageLab software
(Bio-Rad) were used to obtain images and for calculating the
relative quantities and molecular weights of the bands.
Primer ID

Sequence

+15 forward

tcacccaggaatgtcttttttaaAGCTCGAGTCTAGAGGGC

+15 reverse

caggcacagtgcaggagtgtgagcATCGAAACAACCTGGTGAAG

RG forward

gtgcctgtcacccaggaatgtcttttttaaAGGTTGTTTCGATAGCTCG

RG reverse

agtgcaggagtgtgagctgtcgaagcatccGGTGAAGTCTCGCAAGGC

Plasmids
Wild-type (WT) hemagglutinin (HA)-TNPO3 was provided by
Nathaniel Landau of New York University. The C-terminal
Neurology.org/NG

extension constructs “+15” and “RG” were made by insertion
mutagenesis of the HA-TNPO3 plasmid using the Q5 SiteDirected Mutagenesis Kit (NEB E0554S) and the following
primers:
Immunofluorescence
HeLa cells were grown on glass coverslips in a 12-well plate. The
next day, cells were transfected with 1.0 μg of plasmid using
Lipofectamine 2000 and following the manufacturer’s protocol.
Twenty-four hours later, cells were ﬁxed in ice-cold 4% paraformaldehyde in PBS for 15 minutes at RT. Cells were then
washed with PBS 3 times for 5 minutes each and permeabilized
with 0.2% Triton X-100 in PBS for 10 minutes at RT.
Blocking and detection of hemagglutinin only
Cells were incubated in blocking buﬀer made up of 1% BSA in
PBS for 1 hour at RT. Coverslips were then transferred to a humidiﬁed chamber and incubated with Alexa Fluor 488-conjugated
mouse anti-HA antibody diluted 1/200 in blocking buﬀer for
either 2 hours at RT or overnight at 4°C. Coverslips were washed
with PBS 3 times for 5 minutes each at RT. They were then
carefully dipped in molecular-grade water for 10 seconds and
mounted on microscope slides using Mowiol mounting medium.
Blocking and double-labeling of both marker
and hemagglutinin
Cells were incubated in Blocking Buﬀer A (PBS + 1% BSA + 5%
serum of the secondary antibody host) for 1 hour at RT. Coverslips were then transferred to a humidiﬁed chamber and incubated overnight with anti-HA, anti-T-cell-restricted intracellular
antigen-1 (TIA1), RanGAP1 (Santa Cruz Biotechnology), or
Mab414 (BioLegend) in Blocking Buﬀer A. The next day, coverslips were washed 3 times for 5 minutes each with PBS and then
incubated with Alexa Fluor 555–conjugated secondary antibody
diluted 1/500 in Blocking Buﬀer A for 1 hour at RT. Cells were
washed 3 times for 5 minutes each with PBS and then incubated in
Blocking Buﬀer B (PBS + 1% BSA + 5% serum of the primary
antibody host) for 1 hour at RT. Coverslips were then incubated
for 2 hours at RT with Alexa Fluor 488–conjugated mouse antiHA antibody diluted 1/200 in Blocking Buﬀer B. Coverslips were
washed with PBS 3 times for 5 minutes each at RT. They were
then carefully dipped in molecular-grade water for 10 seconds and
mounted on microscope slides using Mowiol mounting medium.
Arsenite assay
Twenty-four hours after transfection, media were removed from
the coverslips and replaced with warm media containing 0.5 mM
arsenite or an equivalent volume of PBS. Cells were incubated
for 45 minutes in a humidiﬁed 37°C, 5% CO2 incubator. After
incubation, media were aspirated, and cells were washed once
with PBS before ﬁxing and staining as described above.
Quantification of TNPO3 foci
Fixed and stained U2OS cells were viewed on low magniﬁcation, and transfected cells were scored as either TNPO3 foci
positive or TNPO3 foci negative. A minimum of 50 cells were
counted for each condition, and at least 3 independent
experiments were conducted.
Neurology: Genetics | Volume 5, Number 3 | June 2019
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Data availability statement
The data that support the ﬁndings of this study are available
from the corresponding author upon reasonable request.

Results
The proband, a 44-year-old man (II-1), was ﬁrst examined at
age 13 months because of unsteady waddling gait and abnormal head control. At age 3 years, he had mild myopathic
facies, narrow palate, and generalized muscle weakness and
atrophy. There were also absent tendon reﬂexes and Gower
sign present when rising from the ﬂoor. Slight extension
contracture was observed in the right elbow, otherwise joint
contractures or hyperlordosis were not present. Cognitive
functions were normal. During childhood, he was unable to
run or walk on toes and heels. The most pronounced weakness
was present in ankle dorsiﬂexion and knee and hip ﬂexion. EMG
showed no abnormalities, muscle enzymes were slightly elevated, whereas other routine laboratory tests yielded normal
results. His functional abilities were stable and weakness nonprogressive until early adulthood. After that, weakness slowly
progressed to encompass most upper and lower limb muscles,
although more markedly proximal muscles.
His mother (I-3) was able to walk at 16 months and had
proximal and distal lower limb and neck ﬂexor weakness and
Gower sign. She also had proximal upper limb weakness.
Hyperlaxity of most joints was noted. The CK level was
normal, and EMG was suggestive of myopathy. During
childhood, generalized muscle weakness was noted. Achilles
tendon reﬂex was normal, others were absent. She could walk
on toes but not on heels. Her disease was also stable until

adulthood, after which it slowly progressed. She started to use
a wheelchair at age 64 years.
The son (III-1) was hypotonic at birth and had slightly high
palate, no contractures. There was no facial weakness or atrophy or hypertrophy of muscles. Tendon reﬂexes and routine laboratory tests were normal. He started to walk with
waddling gait at 13 months. Gower sign was present, and
slight girdle weakness and axillar hypotonia were observed. At
age 7 years, he could not run and had diﬃculties walking on
uneven ground. Trendelenburg was positive. He had no
hyperlordosis or scoliosis. The Medical Research Council
scale score was 3–4/5 in all proximal and distal limb muscles.
His vital capacity was 75% at age 8 years.
Muscle imaging
Muscle MRI of the proband showed generalized and severe
diﬀuse fatty degenerative changes in all pelvic and thigh
muscles and slightly less severe but still diﬀuse changes in all
the distal lower limb muscles (ﬁgure 2). The changes in the
pelvic and thigh muscles were also severe in the mother, although less severe in the hamstrings and anterior compartment of the lower limbs. Early diﬀuse degenerative changes
were seen in all muscles of the son of the proband.
Genetics
The analysis of the MYOcap sequencing data revealed a heterozygous variant c.2757delC p.(R920Gfs*20) in TNPO3
(NM_012470) in II-1 and III-1, and the same mutation was later
conﬁrmed with Sanger sequencing in I-3. The detected variant
was not listed in the Exome Variant Server, Exome Aggregation
Consortium, or 1000 Genomes databases. Other variants suitable for autosomal dominant inheritance were not detected.

Figure 2 Muscle imaging

Severe generalized fatty degenerative
changes in the proband (A). The hamstring muscles and anterior compartment of the lower limbs were
relatively spared in the mother (B).
Mild and diffuse early changes were
seen in the son of the proband more
pronounced in the sartorius, gracilis,
adductor magnus, and peroneus longus muscles (C).

4
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Histopathology
The muscle biopsies obtained from the proband (II-1) and his
mother (I-3) at adult age showed general myopathic changes
including variation in ﬁber size and shape, ﬁber splitting, and
numerous internal nuclei (ﬁgure 3, A and B). Both hypertrophic
and atrophic ﬁbers were present in large numbers, and prominent type 1 ﬁber predominance was observed (>90% type 1
ﬁbers, whereas in the TA muscle, 60%–80% type 1 ﬁbers is
considered normal).12 Very few occasional necrotic and regenerating ﬁbers were present. The nuclear pathology was remarkable, including swollen nuclei with central pallor (ﬁgure
3A), and accumulation of perinuclear/subsarcolemmal basophilic material was a frequent ﬁnding. Cytoplasmic abnormalities
were observed as well, including rimmed vacuoles (ﬁgure 3B),

sarcoplasmic basophilic material (Figure 3, D and F), and even
some cytoplasmic bodies (ﬁgure 3D). Occasional ragged red
ﬁbers were encountered (ﬁgure 3F), and the number of
Cytochrome C oxidase-negative ﬁbers was slightly increased
(5%–10% ﬁbers Cytochrome C oxidase-negative in I-3 at age 48
years). Sporadic targetoid, whorled, and moth-eaten ﬁbers were
also observed (I-3 at age 48 years).
In biopsies taken at young age (II-1 and III-1 at 3 years and 16
months, respectively), there was ﬁber size variation but no internal
nuclei. Sarcoplasmic abnormalities were not observed in routine
histochemical stainings (H&E and Gomori), but the myoﬁbrillar/
cytoskeletal pathology became visible when immunostained for
myotilin, desmin, and tropomyosin, showing several ﬁbers with

Figure 3 Histopathology

Histopathology of patient II-1 TA biopsy (A–E, G–K, M–N, P) shows myopathic changes: fiber size variation
and numerous internal nuclei, some
with central pallor in H&E (A, arrowheads) and rimmed vacuoles in
Herovici (B, arrowheads). Subsarcolemmal TNPO3 accumulation is
observed in TNPO3 IHC staining (C,
arrowheads). A fiber with small cytoplasmic bodies is seen in Gomori trichrome staining (D, black arrowhead)
and a fiber with myofibrillar pathology (D, white arrowhead). In a serial
section, mitochondrial NADH staining
reveals an uneven staining pattern in
central parts of the muscle fibers (E).
Gomori trichrome of patient I-3 TA
biopsy (F) shows a ragged red fiber
(black arrowhead) and myofibrillar
pathology (white arrowhead). Large
(arrowhead) and small myotilin accumulations are observed in IHC staining (G). In IF double staining, p62
(green) and TDP-43 (red) colocalize in
inclusion bodies (H, arrowheads) in
the rimmed vacuolar fiber. The mitochondrial CHCHD10 shows subsarcolemmal accumulation in several
muscle fibers (I). IF double staining of
desmin (green) and alpha-B-crystallin
(red) shows both cytoplasmic and
subsarcolemmal overexpression and
colocalization (J, arrowheads), as does
desmin (green) and tropomyosin (red)
in K. Notably, desmin (green) and
tropomyosin (red) show overexpression in patient III-1 muscle at
only age 16 months (L). In confocal
microscopy, RBM4 (green) is often
excluded from the nuclei (M, arrowheads) in the patient biopsies,
whereas SRRM2 (green) in N shows
strictly nuclear localization in the patient, a pattern similar to control
muscles. Confocal analysis of TNPO3
shows normal nuclear localization in
patient III-1 (O), but often perinuclear
accumulation of TNPO3 in adult patient biopsy (P, arrowheads), which
shows as a nuclear rim. (A–L), scale
bar = 100 μm; (M–P), scale bar =
50 μm. IF = immunofluorescent; IHC =
immunohistochemistry; TA = tibialis
anterior; TNPO3 = transportin-3.

Neurology.org/NG
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accumulation (ﬁgure 3L). However, the rimmed vacuolar pathology, as well as perinuclear basophilic masses, appeared later in
the disease course and was not present at childhood. Type 1 ﬁber
predominance was present as early as at age 3 years (II-1).
Ultrastuctural examination of I-3 and II-1 showed subsarcolemmal
deposits of amorphic material and degenerated mitochondria and
sometimes membranous structures (data not shown). Areas of
myoﬁbrillar disorganization, including Z-streaming, were encountered, as well as sporadic ﬁbers with minicore-like pathology.
The nuclei were large and showed atypical morphology.
Immunohistochemical analysis showed that TNPO3 accumulated subsarcolemmally, surrounding the myonuclei, corresponding to the perinuclear basophilic material observed in
H&E and Herovici (ﬁgure 3C). Other markers present in these
subsarcolemmal masses included desmin, tropomyosin,
CRYAB, and mitochondrial protein CHCHD10 (in addition,
some lysosomal associated membrane protein 2-positive
granules were observed in the perinuclear location.) The accumulated myoﬁbrillar material in the cytoplasm stained for
desmin, myotilin, CRYAB, ubiquitin, and p62/sequestosome 1
(SQSTM1) and, to a lesser extent, for tropomyosin and lysosomal associated membrane protein 2. Rimmed vacuolar ﬁbers
were positive for p62/SQSTM1, microtubule-associated proteins 1A/1B light chain 3, TDP-43, and ubiquitin (ﬁgure 3H).
No gross abnormality of nuclear markers matrin-3 and emerin
was observed with the IF technique. Confocal analysis showed
diﬀuse to granular nuclear localization of TNPO3 in the control
muscle and patient III-1 (age 16 months) (ﬁgure 3O), whereas
Figure 4 Western blotting

in II-1, variable nuclear and/or perinuclear localization was observed (ﬁgure 3P). A similar staining pattern was observed with
RBM4 (ﬁgure 3M), one of the splicing factors TNPO3 binds
and translocates to the nucleus. Another Ser/Arg-rich splicing
factor, SRRM2, showed normal nuclear (speckle) localization in
patient II-1, with no perinuclear accumulation (ﬁgure 3N).
Western blotting
In Western blotting, one band of approximately 96 kD was
observed in both controls and patients (ﬁgure 4A); hence, we
could not diﬀerentiate the mutant isoform from the WT by gel
migration. However, when the protein bands were quantitated, we observed a marked (two- to threefold) increase in
the TNPO3 protein levels in patients II-1 and III-1 compared
with controls (ﬁgure 4B).
Functional studies
Immunoblotting of Hela cells following transient transfection
with plasmids expressing HA-tagged TNPO3-WT, TNPO3
carrying the previously reported 15 amino acid C-terminal
extension (HA-TNPO3+15) or the currently reported
frameshift mutation (HA-TNPO3-RG) (ﬁgure 5A) revealed
similar expression levels and a slight increase in the molecular
weight of HA-TNPO3+15 and HA-TNPO3-RG as expected
(ﬁgure 5B). Immunoﬂuorescence of exogenously expressed
TNPO3 using an HA antibody revealed similar nuclear localization in addition to cytosolic puncta that were signiﬁcantly enriched in HA-TNPO3-WT–expressing cells
compared with TNPO3 mutants (ﬁgure 5, C and D).
To more clearly identify the cytosolic structure containing HATNPO3-WT, we performed dual immunoﬂuorescence with an
antibody to the stress granule (SG) marker TIA1 because it has
recently been reported that nuclear import receptors associate
with SGs. Although HA-TNPO3-WT and HA-TNPO3-RG do
localize to a subset of TIA1-positive SGs, the larger cytosolic
HA-TNPO3-WT puncta do not colocalize even when cells are
treated with arsenite to induce SGs in HeLa cells (ﬁgure 5E).
We reasoned that cytosolic TNPO3 puncta may colocalize with
nuclear pore complexes (PCs) that assemble in the cytoplasm
at structures termed annulate lamellae pore complexes
(ALPCs). In addition to nucleoporins, ALPCs contain much of
the machinery necessary for nuclear transport including RanGAP1 and both nuclear import and export receptors. Coimmunoﬂuorescence with antibodies to nuclear PCs
(Mab414) or RanGAP1 and HA in HeLa cells transfected with
HA-TNPO3-WT or HA-TNPO3-RG demonstrated strong
colocalization at ALPCs in only TNPO3-WT–expressing cells.

Discussion
(A) Western blotting shows approximately 3-fold increase in TNPO3 protein
expression in the patient samples analyzed (III-1 and II-1) compared with the
pooled control sample (C100 and C50). (B) The bands were quantitated by
calculating the relative quantities of TNPO3/MyHC in each sample and
normalizing the control samples average to 1. MyHC = myosin heavy chain;
TNPO3 = transportin-3.
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Only 1 family with TNPO3 mutation causing LGMD1F has
been reported to date.3,4,13 In addition, a patient with sporadic
LGMD harboring a completely diﬀerent heterozygous missense mutation in the C-terminal part of TNPO3 has been
described4,14 The follow-up study on the large family found
Neurology.org/NG

Figure 5 Expression and localization of HA-tagged TNPO3 constructs

(A) Schematic of HA-tagged TNPO3WT, the previously reported
LGMD1F mutation TNPO3+15 or the
currently described frameshift mutation TNPO3-RG. (B) Immunoblot
with anti-HA, TNPO3, or GAPDH of
HeLa cell lysates transfected with
HA-TNPO3-WT, HA-TNPO3+15, or
HA-TNPO3-RG. (C) HA immunofluorescence of HeLa cells transiently
transfected with HA-TNPO3-WT, HATNPO3+15, or HA-TNPO3-RG. HApositive cytosolic puncta (arrows).
(D) Quantitation of the percent of
cells in C with cytosolic HA-TNPO3
puncta (*** p = < 0.0001). (E) Immunofluorescence using antibodies
to HA (green) and TIA1 (red) of HeLa
cells transfected with TNPO3-WT or
TNPO3-RG pre- and post-stress
granule induction with arsenite. HApositive/TIA1-negative
puncta
(arrowheads). (F) Immunofluorescence using antibodies to HA (red)
and RanGAP1 (green) or nucleoporin antibody Mab414 (green) of
HeLa cells transfected with TNPO3WT or TNPO3-RG. Cytosolic puncta
(arrowheads). Scale bars (C, E, and F)
= 20 μm. TNPO3 = transportin-3; WT
= wild type.

that the mutation c.2771delA segregated in the total of 45
individuals of 115 studied family members with the estimated
penetrance rate of 84.7%.5 Age at onset ranged from less than
1 year to 58 years. Based on the onset and the rate of progression, a juvenile form (onset before age 15 years, severe
disability) and an adult form (onset in the third to fourth
decades, slower progression) were presented.3,12 In the juvenile group, 6 patients had onset at age 1 year with delayed
early motor skills. Although our patients had very early-onset
proximal weakness or congenital hypotonia, the disease was
stable during childhood and slow progression started in
adulthood. The youngest of our patients had a mild decrease
in respiratory functions; none had cardiomyopathy or
hyperlordosis. Also, muscle MRI ﬁndings have been variable
Neurology.org/NG

with main involvement of the vastus lateralis, rectus femoris,
sartorius, and gracilis muscles and at later stages of the calf and
peroneus longus muscles.3,6
We report the second transportinopathy family with a novel
but almost identical frameshift mutation in the TNPO3 gene
compared with the one identiﬁed in the ﬁrst family.3,12 The
congenital very early-onset generalized limb weakness and
slow progression in our patients diﬀered from the phenotype
of most of the patients in the primary family, although some
patients with congenital disease also were encountered. Two
of our patients had already very severe fatty degeneration in
most of their lower limb muscles making comparison diﬃcult,
whereas earliest involvement can be observed in the sartorius,
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gracilis, adductor magnus, and peroneus longus muscles
(ﬁgure 2C). In contrast to the previous reports, we found that
TNPO3 protein was quantitatively increased in the patient
muscle and accumulated in the subsarcolemmal and perinuclear areas in the muscle ﬁbers.
The detected mutation c.2757delC is predicted to cause
a frameshift and transfer the stop codon (p.R920Gfs*20). The
predicted outcome on protein level is almost identical to the
original TNPO3 mutation c.2771delA p.*924Cext*15 (the
amino acid sequence changed by the mutations is
underlined):
WT

…TRLFR*

c.2771delA

…TRLFRCSHSCTVPVTQECLF*

c.2757delC

…TGCFDSSHSCTVPVTQECLF*

Actually, there is just a 5 amino acid diﬀerence between the 2
protein products. Hence, it is expected that the pathomechanisms are largely shared as well. Indeed, we found that
expression of the previously reported TNPO3 variant behaved similarly to our reported variant in cell culture. Speciﬁcally, TNPO3-WT localizes to the nuclear envelope and
a cytosolic organelle termed annulate lamellae (ALs). ALs are
cytosolic accumulations of nuclear PCs and the molecular
machinery necessary for nuclear import/export. The function
of ALs and ALPCs is unclear but may serve as repository
necessary for replacement of nuclear pores and import/export
components. The eﬀect of TNPO3 mutations on nuclear pore
function remains to be established. TNPO3 is a nuclear
transport receptor, regulating nucleocytoplasmic shuttling of
several S/R-rich splicing factors. Perinuclear accumulation
and simultaneous nuclear depletion of TNPO3 and RBM4
observed in the patient muscle biopsy are in line with these
mechanisms. Consequently, processing of speciﬁc mRNA
species may be altered, leading to aberrant splicing and expression of muscle genes. However, the nuclear localization of
SRRM2 indicates that these transcription factors have also
other alternatives to TNPO3 for nuclear entry. Physical accumulation of TNPO3 in the perinuclear/subsarcolemmal
regions, shown by IHC and Western blotting, together with
other proteins and organelles, could disturb normal nuclear
functions in several ways. Indeed, the patient biopsies show
nuclear anomalies.
Myoﬁbrillar pathology was present in the patient biopsies in
this study, although less extensively than in conventional
myoﬁbrilliar myopathies such as myotilinopathy or zaspopathy,15 shown by accumulation of myotilin and desmin, as
reported before in the Spanish family.6 As a novel ﬁnding, we
found that the myoﬁbrillar changes were present as early as at
age 16 months, which is in line with the congenital onset of
symptoms. Notably, we did not observe perinuclear TNPO3
accumulation or depletion from nuclei (or other abnormal
localization) at that early stage, suggesting that this pathology
8
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develops later and may contribute to later events in the muscle
pathology. Rimmed vacuolar pathology with p62/SQSTM1,
TDP-43, microtubule-associated proteins 1A/1B light chain
3, and valocin-containing protein-positive material and accumulated autophagosomal membranes at the ultrastructural
level indicate induction of the autophagosomal degradation
pathway. Again, the number of rimmed vacuolated ﬁbers was
rather low. Defects in RNA metabolism are connected to
defective autophagy and rimmed vacuolar pathology, as seen
in multisystem proteinopathy pathologies.16
The muscle histopathologic ﬁndings and experimental data so
far implicate that there may be several possible mechanisms
involved in the transportinopathy molecular pathophysiology.
To elucidate the pathogenic eﬀects of the described TNPO3
mutations, studies clarifying how they aﬀect the nuclear
import/export dynamics will be required. In addition, the
splicing of muscle genes, especially those regulated by the
TNPO3 cargo proteins, needs to be analyzed. However, toxic
proteins often shed little or no light on the functions of the
normal cognate.
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